A Study of Tesetaxel Plus Capecitabine in Patients With Solid Tumors
Status:
Unknown status
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
This study is being performed to confirm the safety of tesetaxel 27 mg/m2 (Day 1) in
combination with capecitabine 2000/mg/m2/day (in 2 equally divided doses on Days 1 through
14) in a 21-day cycle.